Physician profile
Lea Lazar
NPI 1578609335
$2,526.73
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,766 · 2020: $547 · 2021: $214.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $689.88 | 2019 | |
| Allergan, INC. | $263.14 | 2020 | |
| Abbvie INC. | $213.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $197.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $174.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $139.20 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Emd Serono, INC. | $115.29 | 2019 | |
| Eisai INC. | $104.81 | 2019 | |
| Acadia Pharmaceuticals INC | $78.10 | 2019 | |
| Novo Nordisk INC | $49.22 | 2019-2020 | |
| Amarin Pharma, INC. | $48.71 | 2019-2020 | |
| Sanofi Pasteur INC. | $47.84 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $32.17 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $17.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.